X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (561) 561
humans (515) 515
acting somatostatin analog (290) 290
male (274) 274
female (241) 241
endocrinology & metabolism (220) 220
middle aged (194) 194
adult (189) 189
octreotide - therapeutic use (184) 184
octreotide (175) 175
somatostatin - analogs & derivatives (154) 154
aged (125) 125
acromegaly (110) 110
gastroenterology & hepatology (110) 110
somatostatin (110) 110
somatostatin - therapeutic use (110) 110
acromegaly - drug therapy (102) 102
treatment outcome (102) 102
oncology (100) 100
animals (93) 93
sms 201-995 (93) 93
management (85) 85
pharmacology & pharmacy (85) 85
surgery (78) 78
growth-hormone (77) 77
therapy (77) 77
abridged index medicus (76) 76
long-acting octreotide (76) 76
octreotide - administration & dosage (76) 76
long-acting somatostatin (70) 70
medicine & public health (68) 68
tumors (67) 67
neuroendocrine tumors (61) 61
sms-201-995 (60) 60
peptides, cyclic - therapeutic use (59) 59
care and treatment (58) 58
lanreotide (58) 58
somatostatin analogs (58) 58
follow-up (57) 57
antineoplastic agents - therapeutic use (56) 56
medicine, general & internal (56) 56
long-term treatment (53) 53
long-acting formulation (52) 52
antineoplastic agents, hormonal - therapeutic use (51) 51
efficacy (50) 50
octreotide - adverse effects (48) 48
diabetes (47) 47
cancer (46) 46
somatostatin - administration & dosage (45) 45
acting somatostatin analogs (42) 42
adolescent (42) 42
growth-factor-i (42) 42
aged, 80 and over (41) 41
secretion (41) 41
growth hormone (40) 40
insulin (40) 40
secreting pituitary-adenomas (39) 39
analysis (38) 38
health aspects (38) 38
neuroendocrine tumors - drug therapy (38) 38
injections, subcutaneous (36) 36
retrospective studies (36) 36
chemotherapy (35) 35
delayed-action preparations (35) 35
internal medicine (35) 35
somatostatin analogues (35) 35
dose-response relationship, drug (34) 34
insulin-like growth factor i - metabolism (34) 34
octreotide - pharmacology (34) 34
quality of life (34) 34
research (34) 34
acromegalic patients (33) 33
drug therapy (33) 33
gastrointestinal agents - therapeutic use (33) 33
pituitary neoplasms - drug therapy (33) 33
slow-release lanreotide (33) 33
somatostatin - adverse effects (33) 33
endocrinology (32) 32
peptides, cyclic - administration & dosage (32) 32
tumor shrinkage (32) 32
diagnosis (31) 31
pegvisomant (31) 31
follow-up studies (30) 30
transsphenoidal surgery (30) 30
acromegaly - etiology (29) 29
acromegaly - therapy (29) 29
rats (29) 29
time factors (29) 29
blood glucose - metabolism (28) 28
glucose (28) 28
peptides, cyclic - adverse effects (28) 28
physiological aspects (28) 28
prognosis (28) 28
somatostatin analog (28) 28
combined modality therapy (27) 27
igf-i (27) 27
pancreatic neoplasms - drug therapy (27) 27
pharmacokinetics (27) 27
clinical trials (26) 26
expression (26) 26
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (666) 666
French (9) 9
German (6) 6
Spanish (6) 6
Hungarian (1) 1
Korean (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9903, pp. 1485 - 1495
Journal Article
Journal Article
Endocrine, ISSN 1355-008X, 3/2017, Volume 55, Issue 3, pp. 872 - 884
To date, no data are available on the effects of long-term combined treatment with somatostatin analogues (SA) and pegvisomant (PEG) on cardiovascular... 
Cardiac performance | Somatostatin analogues | IGF-I | Pegvisomant | Science, Humanities and Social Sciences, multidisciplinary | Acromegaly | Internal Medicine | Metabolic syndrome | Pituitary tumors | Cardiac structure | Medicine & Public Health | Left ventricular hypertrophy | Diastolic dysfunction | Insulin resistance | Diabetes | Endocrinology | Ejection fraction | Acromegalic cardiomyopathy | ACTING OCTREOTIDE | COMBINATION THERAPY | INSULIN SENSITIVITY | PATIENTS RESISTANT | TUMOR SHRINKAGE | ENDOCRINOLOGY & METABOLISM | LANREOTIDE AUTOGEL | HORMONE RECEPTOR ANTAGONIST | GLUCOSE-TOLERANCE | CARDIOVASCULAR RISK | GROWTH-FACTOR-I | Somatostatin - analogs & derivatives | Echocardiography | Acromegaly - diagnostic imaging | Humans | Middle Aged | Male | Myocardium - pathology | Human Growth Hormone - analogs & derivatives | Heart - diagnostic imaging | Acromegaly - drug therapy | Human Growth Hormone - therapeutic use | Human Growth Hormone - pharmacology | Heart - drug effects | Adult | Female | Blood Pressure - drug effects | Blood Pressure - physiology | Body Weight - physiology | Drug Therapy, Combination | Acromegaly - pathology | Complications and side effects | Physiological aspects | Somatostatin | Cardiovascular diseases | Health aspects | Risk factors | Heart | Fasting | Insulin-like growth factor I | Polyethylene glycol | Lipids | Blood pressure | Ventricle | Insulin | Heart diseases | Index Medicus
Journal Article
Journal Article
Journal Article
Neuroendocrinology, ISSN 0028-3835, 09/2015, Volume 102, Issue 1-2, pp. 18 - 25
Journal Article
Lung Cancer, ISSN 0169-5002, 2011, Volume 76, Issue 1, pp. 84 - 88
Abstract Background Long acting somatostatin analogues combined with platinum analogues have demonstrated an antiproliferative effect on growth of human SCLC... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | VEGFR2 | NSE | Small cell lung cancer | VEGFC | Antiproliferative effect | IGF1 | HER2 | Long acting somatostatin analogues | VEGFA | PROTEIN | ANGIOGENESIS | CHEMOTHERAPY | PHASE-III TRIAL | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | CARCINOMAS | RECEPTORS | ERLOTINIB | ENDOTHELIAL GROWTH-FACTOR | Adrenal Gland Neoplasms - drug therapy | Bone Neoplasms - mortality | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Somatostatin - administration & dosage | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Liver Neoplasms - mortality | Small Cell Lung Carcinoma - drug therapy | Peptides, Cyclic - administration & dosage | Feasibility Studies | Adrenal Gland Neoplasms - mortality | Brain Neoplasms - secondary | Biomarkers, Tumor - metabolism | Adrenal Gland Neoplasms - secondary | Female | Receptors, Somatostatin - metabolism | Bone Neoplasms - drug therapy | Brain Neoplasms - mortality | Liver Neoplasms - secondary | Paclitaxel - administration & dosage | Somatostatin - analogs & derivatives | Enzyme-Linked Immunosorbent Assay | Octreotide - analogs & derivatives | Liver Neoplasms - drug therapy | Carboplatin - administration & dosage | Survival Rate | Brain Neoplasms - drug therapy | Small Cell Lung Carcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Small Cell Lung Carcinoma - mortality | Neoplasm Staging | Antimitotic agents | Care and treatment | Heterocyclic compounds | Lung cancer | Lung cancer, Small cell | Antineoplastic agents | Cancer | Index Medicus
Journal Article